Cerus Corporation (CERS)
Market Cap | 314.31M |
Revenue (ttm) | 191.72M |
Net Income (ttm) | -31.56M |
Shares Out | 184.89M |
EPS (ttm) | -0.17 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 400,457 |
Open | 1.700 |
Previous Close | 1.720 |
Day's Range | 1.680 - 1.720 |
52-Week Range | 1.210 - 3.080 |
Beta | 1.26 |
Analysts | Buy |
Price Target | 3.25 (+91.18%) |
Earnings Date | Jul 31, 2024 |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ... [Read more]
Financial Performance
In 2023, Cerus's revenue was $186.80 million, a decrease of -0.81% compared to the previous year's $188.32 million. Losses were -$37.49 million, -12.37% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3.25, which is an increase of 91.18% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/x/l/press3-2489965.jpg)
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood ...
![](https://cdn.snapi.dev/images/v1/h/u/press20-2479652.jpg)
Cerus Corporation Celebrates World Blood Donor Day 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Bl...
![](https://cdn.snapi.dev/images/v1/1/c/conf8-2443355.jpg)
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institu...
![](https://cdn.snapi.dev/images/v1/c/i/press19-2407507.jpg)
Cerus Corporation Announces First Quarter 2024 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total rev...
![](https://cdn.snapi.dev/images/v1/r/d/conf20-2378075.jpg)
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock...
![](https://cdn.snapi.dev/images/v1/s/d/press19-2341724.jpg)
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet P...
![](https://cdn.snapi.dev/images/v1/u/b/press2-2330800.jpg)
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (...
![](https://cdn.snapi.dev/images/v1/k/i/press5-2309512.jpg)
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-qua...
![](https://cdn.snapi.dev/images/v1/g/7/conf5-2283493.jpg)
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the cl...
![](https://cdn.snapi.dev/images/v1/f/q/conf11-2255332.jpg)
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Dig...
![](https://cdn.snapi.dev/images/v1/h/5/press7-2220167.jpg)
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-...
![](https://cdn.snapi.dev/images/v1/j/e/press15-2137489.jpg)
Cerus Corporation Announces Third Quarter 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total...
![](https://cdn.snapi.dev/images/v1/5/g/press15-2133988.jpg)
Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace
DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...
![](https://cdn.snapi.dev/images/v1/n/t/conf5-2111009.jpg)
Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the ...
![](https://cdn.snapi.dev/images/v1/a/0/press7-2096720.jpg)
Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from ...
![](https://cdn.snapi.dev/images/v1/4/t/press5-2079701.jpg)
Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will fo...
![](https://cdn.snapi.dev/images/v1/b/k/conf17-2059449.jpg)
Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Co...
![](https://cdn.snapi.dev/images/v1/8/w/press3-2002451.jpg)
Cerus Corporation Announces Second Quarter 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total re...
![](https://cdn.snapi.dev/images/v1/2/l/conf15-1977835.jpg)
Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the ...
![](https://cdn.snapi.dev/images/v1/v/o/press6-1935550.jpg)
Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) ...
![](https://cdn.snapi.dev/images/v1/q/f/press8-1933625.jpg)
Cerus Corporation Celebrates World Blood Donor Day 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023. In 2005, the World Health Assembly designated June 14 as World Bl...
![](https://cdn.snapi.dev/images/v1/m/l/press14-1920664.jpg)
Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U...
![](https://cdn.snapi.dev/images/v1/0/2/press3-1872909.jpg)
Cerus Corporation Announces First Quarter 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total rev...
![](https://cdn.snapi.dev/images/v1/k/j/conf14-1845695.jpg)
Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock...
![](https://cdn.snapi.dev/images/v1/u/r/press4-1775398.jpg)
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2022.